Anne & Allan Bank Centre for
Clinical Research Trials is established
positioned at the forefront of
dementia reasearch. As of 2024, it
boasts the largest number of ongoing
therapy and intervention trials in
Canada to treat and prevent dementia.
Baycrest@Home, an
innovative program, helps
older adults stay in their
homes longer and lends
support to caregivers.
Possibilities by Baycrest
TM
,
a revolutionary memory
care model, creates uniquely
customized experiences so
individuals living with dementia
can live a life of purpose,
fulfilment and dignity.
The Virtual Behavioural
Medicine Program (VBM)
expands our reach to help
dementia patients and
reduce wait times. Doctors
assess patients remotely and
prescribe treatments that
keep them at home longer.
Baycrest Academy for
Education and Research
(BARE) maximizes our
impact with increased
collaboration in
knowledge discovery and
dissemination, amplifying
our reach and influence.
The Bresver
Neuromodulation
& Therapeutics
Program is launched
to investigate non-
invasive neuromodulation
strategies, as one of
the most promising
treatments for
Alzheimer's disease.
Baycrest starts building
the Pamela & Paul Austin
Artificial Intelligence (AI)
Platform to incorporate
artificial intelligence in the
delivery of timely diagnosis
and care for patients with
cognitive difficulties.
Canadian Consortium
Neurodegeneration in
Aging (CCNA) moves its
scientific headquarters to
Baycrest. CCNA, Canada's
largest national dementia
research initiave, brings
together researchers who
work to treat and prevent
dementia.
2022 2024
2020 2021 2023
BrainMatters •Fall/Winter 2024 • 15
ACHIEVEMENTS AND PROGRESS
